Abstract MUC1 is a transmembrane mucin with important functions in normal and transformed cells, carried out by the extracellular domain or the cytoplasmic tail. A characteristic feature of the MUC1 extracellular domain is the variable number of tandem repeats (VNTR) region. Alternative splicing may regulate MUC1 expression and possibly function. We developed an RT-PCR method for efficient isolation of MUC1 mRNA isoforms that allowed us to evaluate the extent of alternative splicing of MUC1 and elucidate some of the rules that govern this process. We cloned and analyzed 21, 24, and 36 isoforms from human tumor cell lines HeLa, MCF7, and Jurkat, respectively, and 16 from normal activated human T cells. Among the 78 MUC1 isoforms we isolated, 76 are new and different cells showed varied MUC1 expression patterns. The VNTR region of exon 2 was recognized as an intron with a fixed 5 0 splice site but variable 3 0 splice sites. We also report that the 3506 A/G SNP in exon 2 can regulate 3 0 splice sites selection in intron 1 and produce different MUC1 short isoform proteins. Furthermore, the SNP A to G mutation was also observed in vivo, during de novo tumor formation in MUC1 ?/-Kras G12D/? Pten loxP/loxP mice. No specific functions have been associated with previously reported short isoforms. We now report that one new G SNP-associated isoform MUC1/Y-LSP, but not the A SNPassociated isoform MUC1/Y, inhibits tumor growth in immunocompetent but not immunocompromised mice.
Introduction
Alternative splicing of eukaryotic pre-mRNAs can enhance the proteome diversity and contribute to genome evolution and gene regulation [1] [2] [3] [4] . Up to 95 % of human premRNAs that contain more than one exon are alternatively spliced to yield multiple mRNA isoforms [5] [6] [7] . Aside from its role in physiological adaptation of cells [8] , alternative splicing has been shown to occur in human diseases, including cancer [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Detection of splice variants is considered more reliable than transcription-level differences in discriminating tumor from normal tissue [19, 20] .
The mucin family of epithelial proteins currently comprises 20 members (MUC1-MUC20) [21] . MUC1, the first identified and most studied mucin is a high-molecularweight transmembrane glycoprotein that is overexpressed and hypoglycosylated in most adenocarcinomas, including breast, lung, colon, pancreas, stomach, prostate, and ovarian tumors [22] . Though it is encoded as a single protein, MUC1 is expressed as a type I transmembrane heterodimer with a large extracellular a-subunit non-covalently bound to a smaller transmembrane b-subunit [23] . The MUC1 gene is located on the human chromosome 1q21 and Electronic supplementary material The online version of this article (doi:10.1007/s00262-012-1325-2) contains supplementary material, which is available to authorized users.
contains seven exons. The extracellular fragment encoded by exons 1-4 is dominated by the VNTR domain located in exon 2. Exon 2 consists of tandemly repeated (between 20 and 200 times, depending on genotype) units of 60 base pairs encoding a proline-rich sequence PDTRPAPG-STAPPAHGVTSA. The rigid structure of this protein domain, which we previously analyzed by 1D and 2D NMR [24, 25] , can extend 300-500 nm above the cell surface, towering over other cell surface molecules. While the MUC1 extracellular domain plays important roles in cell-cell and cell-matrix interactions [26, 27] , it has also been shown to regulate chemotaxis of cells of the innate immune system [28] . The smaller b-subunit of MUC1 (*20 kDa) encoded by exons 4-7 contains a short extracellular portion, a transmembrane region, and a short cytoplasmic tail with seven phosphorylation sites that support the role of MUC1 as a signaling molecule [21, 29] .
MUC1 was characterized first by us [30] and later by others as a tumor antigen and a target for immunotherapy, as well as a molecule with immunosuppressive [28, 31] and tumor-promoting functions [32, 33] . MUC1 can promote malignant transformation by regulating the function of b-catenin [34] and p53 [35] , and by repressing a microR-NA (miR-322) via a feedback loop [36] . All of these functions have been ascribed to the whole molecule (MUC1/TR) or the truncated form consisting of the transmembrane domain and the cytoplasmic tail. The wellknown MUC1 isoforms are the full-length form encoded by all 7 exons with the VNTR region (MUC1/TR) and the short isoforms lacking VNTR, such as MUC1/X, MUC1/Y, MUC1/Z, and MUC1/ZD [37] [38] [39] [40] . The overall prevalence, mechanism of generation, and individual contributions, if any, of MUC1 isoforms to the known functions of MUC1 are not defined. We report here results from cloning and sequencing of a large number of MUC1 mRNA short isoforms from tumor cells and normal cells using our optimized RT-PCR-based method that allowed us to compare the expression pattern of MUC1 isoforms in different cells and to identify specific alternative splicing events that led to their generation. We discuss possible biological roles and, in the case of MUC1Y-LSP we isolated, show that it can interfere with tumor growth in vivo.
Materials and methods

Ethics statement
Mice were maintained or bred in specific pathogen-free conditions at the University of Pittsburgh and treated under the guidelines in accordance with the protocol No. 0905822B-3 approved by the Institutional Animal Care and Use Committee.
Cell culture and flow cytometry All cell lines were purchased from the American Type Culture Collection (ATCC) unless otherwise indicated. Human tumor cell lines HeLa (cervical cancer), MCF7 (breast cancer), Jurkat (T lymphoma), and DM6 (melanoma) were cultured in RPMI 1640 (GIBCOL BRL) medium supplemented with 10 % fetal bovine serum (GIBCOL BRL), 10,000 U/L penicillin (Sigma), 10,000 lg/L streptomycin (Sigma), and 2 mmol/L L-glutamine (GIBCOL BRL). Human PBMCs from healthy donors were obtained from the Central Blood Bank of Pittsburgh and cultured in RPMI 1640 supplemented with 10 % human AB serum, 10,000 U/L penicillin, 10,000 lg/ L streptomycin, 2 mmol/L L-glutamine, 20 ,000 U/L IL-2, and 10 mg/L phytohemagglutinin (PHA), at 37°C, 6 % CO2 for 3 days. RMA mouse T lymphoma cell line [18] was cultured in DMEM (GIBCOL BRL) supplemented with 10 % fetal bovine serum (GIBCOL BRL), 10,000 U/L penicillin (Sigma), 10,000 lg/L streptomycin (Sigma), 2 mmol/L L-glutamine (GIBCOL BRL), 1 % non-essential amino acids (GIBCOL BRL), 1 mM sodium pyruvate, and 0.1 mM beta-mercaptoethanol (Gibco). A total of 2 9 10 5 cells were used for flow cytometry analysis of MUC1 expression. In brief, cells were suspended in staining buffer (1 % BSA in PBS, pH7.4) and FITC mouse anti-Human CD227 (MUC1) (BD) or FITC mouse IgG1(BD) was added and incubated on ice for 30 min; and then the cells were washed 29 with staining buffer, and samples were run on BD LSRII flow cytometer.
Primers
The following primers were used for the PCRs: P1S: 5 0 -GCG CCT GCC TGA ATC TGT TC- 
Amplification and cloning of MUC1 isoforms
Trizol
TM reagent (Invitrogen) or AllPrep DNA/RNA Mini Kit (Qiagen) was used to extract total RNA and genomic DNA from HeLa, MCF7, Jurkat cells, and PHA-activated human T cells according to the protocol provided by the manufacturer. Reverse transcription was performed using SuperScript TM First-Strand Synthesis System (Invitrogen) with Oligo (dT) [12] [13] [14] [15] [16] [17] [18] primers according to the instruction manual.
The method takes advantage of the first and last exons being constitutive exons included in most isoforms. Two pairs of primers binding to the first and last exons were designed. One pair (P1S-P1A) for the first PCR amplification of different possible alternatively spliced variants from reverse-transcribed products, and the second pair (P2S-P2A) for eliminating the false positives of the first round using colony PCR. The PCR conditions were as following: First PCR: 109 ExTaq (TaKaRa Bio Inc., Japan) buffer 5 lL, dNTP (2.5 mM) 5 lL, P1S (10 lM) and P1A (10 lM) primer mixture 5 lL, cDNA 2 lL, ExTaq 0. After 30 or 35 rounds of PCR, bands were resolved on a 1 % TAE agarose gel (Supplemental Fig 1) . Individual bands were recovered and purified with Promega Wizard PCR Preps DNA Purification System or QIAquick Gel Extraction Kit, cloned into pGEM-T (Promega) or pCR 
4-TOPO
Ò vector (Invitrogen) according to the instructions provided, and transformed into DH5a competent cells. Positive colonies were selected in Luria-Bertani (LB) 1 % agar plates containing 100lg/mL ampicillin at 37°C after 16-20 h.
To eliminate colonies that contained non-specific PCR products, 20 colonies from each transformation were picked for colony PCR analysis. 109 ExTaq buffer 2 lL, dNTP (2.5 mM) 2 lL, P2-S (10 lM) and P2-A (10 lM) mixture 2 lL, ExTaq 0.1 lL, and H 2 O 13.9 lL were mixed together. The transformed E.coli colonies were sampled and pipetted into the PCR mixtures. The PCR condition was as follow: 94°C, 5 min, (94°C, 30 s; 65°C, 30 s; 72°C, 1 min) 9 25; 72°C, 7 min. All PCR products were run on 1 or 2 % TAE agarose gel (Supplemental Fig 2) .
Sequencing of PCR products
Transformants confirmed by colony PCR were amplified in LB medium with 100 lg/mL ampicillin at 37°C, and recombinant plasmids were purified with QIAPrep Spin Miniprep Kit. DNA fragments were amplified from genomic DNA(100 ng) from different cell lines using TR-S and TR-A primers: 109 ExTaq buffer 5 lL, dNTP (2.5 mM) 5 lL, TR-S (10 lM) and TR-A (10 lM) primer mixture 5 lL, cDNA 2 lL, ExTaq 0.5 lL, H 2 O 32.5 lL, 94°C, 5 min; (94°C, 40 s; 58°C, 40 s; 72°C, 1 min) 9 35; 72°C, 7 min. PCR fragments were purified with QIAPrep Kit. All DNA sequencing was done at the DNA Sequencing Facility of The University of Pittsburgh. The sequences were analyzed by searching BLASTn using MUC1 gene (GenBank No. M61170) as a template.
Cloning of MUC1 short isoforms generated by MUC1/TR pcDNA3 plasmids (Invitrogen) containing MUC1/42TR were transfected into HeLa cell lines using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's instruction manual. Twenty-four hours after transfection, total RNA was isolated and RT-PCRs were done using primers pcDNA-S and P2A. Bands were recovered and cloned into pCR 
De novo tumor formation in conditional mice
We generated triple transgenic MUC1
?/-Kras G12D/? PtenloxP/loxP mice by crossing MUC1
?/-transgenic mice (purchased from Dr. S. Gendler, Mayo Clinic, Scottsdale, AZ) that carry 1-2 copies of MUC1 gene and express human MUC1 under the endogenous promoter [41] with the previously described Kras G12D/? Pten loxP/loxP mice [42] . Genotyping was performed as previously described [43, 44] .
To generate tumors, Cre recombinase encoding adenovirus [Ad5CMVCre (AdCre)] obtained from the University of Iowa Gene Transfer Vector Core was administered either under the ovarian bursa (IB) or intraperitoneally (i.p.) as described by us and others [42, 45] . For IB injections, the mice received 5 lL of 2.5 9 10 7 plaqueforming units (PFU) of Ad5CMVCre delivered to the ovarian surface epithelium (OSE) of left ovary only, during survival surgery. The contralateral ovary served as control. For the intraperitoneal experiments, we administered 100 lL of AdCre (5 9 10 8 PFU) per animal. Mice were killed when moribund (hunched appearance, ruffled fur, unable to reach for food or water). Tumors from the primary and metastatic sites were harvested and processed for DNA extraction as well as for paraffin embedding (histology).
Tumor growth in vivo 1 9 10 5 transfected or untransfected RMA cells were subcutaneously injected into the thighs of C57BL/6 (6-8 weeks), NOD.CB17-Prkdc scid /J (6-8 weeks) (The Jackson Laboratory, Bar Harbor, Maine), or MUC1.Tg mice (6-8 weeks, Mayo Clinic, Scottsdale, AZ). Mice were killed within 2-3 weeks and tumors were measured.
In vivo tumor cell killing assay
In brief, 1 9 10 7 RMA, RMA-Y-LSP, RMA-Y, and RMA-22TR cells in PBS containing 1 % FBS were labeled with 1 lM (low) or 10 lM (high) CFSE (Invitrogen) at 37°C for 15 min, then transferred on ice and in 10 mL cold complete DMEM for additional 10 min. RMA-low and RMA-Y-LSP-high, RMA-low and RMA-Y-high, RMAlow and RMA-22TR-high were mixed together at 1:1 ratio. A total of 1 9 10 6 mixed cells were injected intraperitoneally into MUC1.Tg mice. Surviving cells were recovered after 44 h, and flow analysis was run to analyze CFSE-low versus CFSE-high cell populations on LSR II (BD Biosciences).
Results
Tumor cell lines express a large variety of MUC1 isoforms
To select candidate cell lines for our molecular studies of MUC1 isoforms, we stained several cell lines for MUC1 expression. Flow cytometry analysis using an antibody binding to the VNTR showed that almost all epithelial MCF7 (99.6 %) and HeLa (98.1 %) cells and a portion of activated T cells (24.2 %) expressed MUC1/TR on the cell surface, while very few if any of the T-cell leukemia Jurkat cells (1.5 %) were MUC1 positive. However, in Jurkat cells, MUC1/TR seems to be confined to the cytoplasm, as intracellular staining revealed that 84.6 % of cells were MUC1/TR? (Fig. 1) . These different levels and patterns of expression provided a good setting in which to explore the extent and diversity of alternative splicing of MUC1.
Total RNAs were isolated from the tumor cell lines for RT-PCR amplification and cloning of MUC1 short isoforms. Analysis of cloned and sequenced cDNA of MUC1 from the three tumor cell lines yielded a total of 68 isoforms, 21 from HeLa (Fig. 2a) , 24 from MCF7 (Fig. 2b) , and 36 from Jurkat cells (Fig. 2c) . Among the 68 isoforms, the previously reported MUC1/Y and MUC1/Z were also included. These two isoforms, as well as MUC1/Y-LSP which is one of the new isoforms we isolated, were seen in all three tumor lines. Of the total of 68 isoforms, the open reading frames (ORFs) of 31 isoforms are in frame with the full-length MUC1/TR. Twenty-one of these have the potential to encode transmembrane forms, while 10 could encode only secreted proteins, having spliced out exon 5 that encodes the transmembrane domain.
Premature termination codons (PTCs) were observed in 37 isoforms (38.1 % in HeLa, 12.5 % in MCF-7, and 75 % in Jurkat), occurring more than 50 nucleotides upstream of the final splice junction, suggesting that these isoforms may be the potential target for nonsense-mediated mRNA decay (NMD), a surveillance mechanism that selectively degrades mRNAs that would encode premature transcription termination codons [46] .
MUC1 isoforms are generated through different alternative splicing events
We examined the sequence of the cloned MUC1 isoforms and identified that they could be generated through different types of alternative splicing, including exon skipping, alternative 5 0 splice sites, alternative 3 0 splice sites, and intron retention. Only exon 1 (E1) did not seem to be alternatively spliced. The most frequent alternative splicing event was exon skipping that involves exons E3, E4, and E5, with E4 having the highest skipping rate. E6 skipping occurred only in one isoform (MUC1/M16) derived from MCF7. Intron retention involving intron 1 (full) and intron 6 (partial) was detected in Jurkat cells. Only one isoform (MUC1/M11) from MCF7 showed partial intron 6 retention.
Both conventional and cryptic splice sites are used in alternative splicing of the MUC1 gene. To produce the fulllength MUC1/TR containing all 7 exons, the conventional splice sites in the six introns are used. In intron 1, the cryptic splice sites used are 5 0 site 3222 and 3096 and 3 0 splice sites 3252, 3261, 3471, 3507, and 3534. Usage of the 3 0 splice site 4945 located in exon 5 is always associated with exon skipping, including E4 skipping, E3-E4 doubleskipping, and E3-E4 plus part of E2 skipping. This can be observed in HeLa and MCF7, but not in Jurkat cells. In intron 6, different 5 0 and 3 0 cryptic splice sites usage can cause partial intron retention, mostly observed in Jurkat cells yielding isoforms MUC1/J1, J10, J12, J13, and J14. The VNTR region in E2 was spliced out in all MUC1 short isoforms using a single cryptic 5 0 splice site at position 3600 and multiple cryptic 3 0 splice sites at positions 4205, 4235, 4259, 4278, 4192, and 4120. These results suggest that tumor cells can produce vastly different forms of MUC1 simultaneously by multiple alternative splicing pathways.
Differences and similarities in the expression of MUC1 isoforms in normal T cells versus epithelial tumor cells
We [47] and others [48, 49] have shown that primary T cells express MUC1 upon activation. Here, we used PHAactivated T cells to test whether MUC1 mRNA isoforms are made by normal cells and what, if any, differences there might be in the specific alternative splicing mechanisms between normal and tumor cells. cDNAs from PHA-activated T cells from a healthy donor were used to isolate MUC1 mRNA isoforms using the same PCR method as for tumor cells. In all, 16 new isoforms were cloned (Fig. 2c) . Our analysis revealed that the same mechanisms seen in tumor cells, exon skipping, alternative 5 0 splice sites, and alternative 3 0 splice sites were also used by primary T cells to produce these isoforms, with the exception of complete intron retention. The VNTR region is spliced out as in tumor cells with the same 5 0 splice site, some common 3 0 splice sites (4205, 4259, 4278, 4120, 4192), and one unique 3 0 splice site (3934) whose product (MUC1/T1) has a part of a degenerate VNTR (dTR) region. The 3 0 splice sites at positions 4120 and 4192 and the 3096 5 0 splice site were only used by Jurkat (T-cell lymphoma) and normal T cells. Normal T cells share other isoforms with Jurkat but not with HeLa and MCF7 cells, including MUC1/G-LSP, T4, T11, T12, suggesting that these isoforms may be T cell (Fig. 3) .
The VNTR-containing region of exon 2 is recognized as an intron A common feature of all the short MUC1 isoforms is that the VNTR region is spliced out, implying that this region could be recognized by the spliceosome as an intron. To elucidate whether the VNTR region can be spliced out in an already spliced mature MUC1 mRNA containing all seven exons, we transfected the pcDNA3 expression vector containing MUC1 cDNA with 42 TRs (pcDNA3-MUC1/ 42TR) into HeLa cells. In order to isolate mRNA products from transcripts produced by the plasmid encoded MUC1 and not from the endogenous MUC1, we used a pair of primers combining one that binds to the MUC1 sequence and the other to the vector sequence. If the VNTR region is recognized as an intron, we expected the transcripts of MUC1/42TR to be spliced to generate short isoforms devoid of VNTRs. The results (Fig. 4) showed that short MUC1 mRNA isoforms MUC1/Y and MUC1/G were among the products generated by pcDNA3-MUC1/42TR, indicating that mature MUC1/TR mRNAs may be further alternatively spliced after being produced from the MUC1 pre-mRNA and thus could serve as another source for generating short isoforms in addition to the MUC1 premRNA.
A/G SNP can regulate production of MUC1 short isoforms and can change during cell transformation
In exon 2 of the MUC1 gene (GenBank No. M61170), there is an A/G SNP (ref SNP ID: rs4072037) at nucleotide 3506 that was previously reported to dictate the 3 0 splice site selection of 3498 (when it is A) versus 3471 (when it is G) in the full-length MUC1/TR in tumor [50] as well as MUC1/TR and MUC1 devoid of TR in normal cells [51] , resulting in a 27 bp length difference in the signal peptideencoding region. We wanted to see whether this rule also held in the generation of MUC1 short isoforms devoid of TR region in the cells we used and whether there were any exceptions. We sequenced the MUC1 gene fragment containing the SNP in all the cell lines and found that it is A/G in HeLa, MCF7, and Jurkat cells and G/G in normal T cells (Fig. 5a ). Of the 68 short isoforms isolated from the three tumor cell lines, some have A at 3506 while others have G (19 % in HeLa, 41.7 % in MCF7, and 47.2 % in Jurkat), indicating that both MUC1 alleles are transcribed and alternatively spliced at their appropriate 3 0 splice sites. The exceptions were seven short isoforms that showed no 3 0 splice site use and thus complete intron 1 retention, and two other short isoforms, MUC1/J3 and MUC1/J7, that used other 3 0 splice sites. MUC1/J3 that has a G at position 3506 but was spliced at 3 0 splice site 3250 and MUC1/J7 with an A at position 3506 used the 3 0 splice site 3259. These results indicated that MUC1 3506 A/G SNP could produce different MUC1 isoforms with different signal peptide coding sequences by using at least four different 3 0 splice sites. Intron 1 retention could happen under both 3506 A and 3506 G.
We then wanted to see how the 3506 A/G SNP affects the MUC1 short isoforms expression at the protein level. Four MUC1 short isoforms, including two A allele-associated isoforms MUC1/Y, MUC1/S1 and two G alleleassociated isoforms MUC1/Y-LSP, MUC1/S2 (Fig. 5b) , were transfected into DM6 cell line. Western blotting results showed that MUC1/Y-LSP protein is slightly larger than MUC1/Y as predicted, but MUC1/S1 and MUC1/S2 exhibited a different protein pattern than predicted (Fig. 5b) , with MUC1/S1 having one band while MUC1/S2 had two bands (Fig. 5c) . Obviously, a different signal peptide coding sequence in the short MUC1 isoforms could generate different mature protein products.
To examine the occurrence of 3506 A/G SNP in de novo tumors in vivo, we employed triple transgenic mice that express human MUC1 as self [41] and carry conditional (loxP) engineered loci in the Kras and Pten genes [42] . The MUC1
?/-Kras G12D/? Pten loxP/loxP (or briefly MUC1KrasP-ten) mice mirror the tissue MUC1 expression seen in humans and progress to MUC1-positive tumors of the ovaries and peritoneal cavity. Injection of Cre-encoding adenovirus under the ovarian bursa triggered the development of endometrioid ovarian tumors in mouse 2347 (Fig. 6a) , while intraperitoneal (i.p.) AdCre injection triggered peritoneal carcinomatosis in one male (2949) and one female (2688) mouse (Fig. 6a) . Our SNP analysis of the tumor DNA using 3506 SNP A/G-specific PCR showed that in 2 of 3 MUC1KrasPten mice that are normally 3506 A/A, the tumors carry both 3506 A and 3506 G, indicating that A to G mutation happened during the in vivo tumor formation.
MUC1/Y-LSP isoform inhibits tumor growth
We next sought to test whether the short isoforms MUC1/Y and MUC1/Y-LSP, when expressed in a MUC1-negative tumor cell line, might affect its growth in vivo. To address this, we transfected MUC1/Y, MUC1/Y-LSP, and fulllength MUC1/TR with 22 tandem repeats (MUC1/22TR) into the mouse tumor cell line RMA and later selected the MUC1-positive, stable transfectants. When injected subcutaneously, RMA-MUC1/22TR and RMA-MUC1/Y cells grew progressively in two immunocompetent mouse strains, C57BL/6 and C57BL/6MUC1.Tg, while RMA-MUC1/Y-LSP cells did not (Fig. 7a) . Though the growth rate of the RMA, RMA-MUC1/Y, RMA-MUC1/Y-LSP, and RMA-MUC1/22TR cells is similar in vitro (data not shown), the in vivo CFSE assay showed that after intraperitoneal injection into MUC1.Tg mice, most RMA-MUC1/Y-LSP cells were killed over a period of 44 h, while the parental RMA, RMA-Y, and RMA-22TR survived, though in different ratios (Fig. 7b) , indicating that the expression of MUC1/Y-LSP targeted the tumor cells for destruction through a so far unknown mechanism. One mechanism we considered was the killing of tumor cells by NK cells. To test this possibility, we injected the RMA-MUC1/Y-LSP tumor cells into immunocompromised NOD.CB17-Prkdc scid /J mice (3/3) (Fig. 7a ) that have NK cells but lack T and B cells. Our results show that all the mice injected developed tumors, ruling out NK-mediated lysis as the cause for the lack of in vivo tumor growth in immunocompetent mice. 
Discussion
Alternative splicing has an important role in the regulation of expression of genes associated with many diseases, including cancer. High-throughput approaches such as microarray chips [52] , digital polony exon profiling technology [53] , and deep sequencing [5] [6] [7] have been used for predicting or detecting splicing events. However, none of these methods yields splicing products for biochemical and functional studies. We adapted an RT-PCR-based method for a comprehensive study of alternative splicing and resulting isoforms of a biologically important molecule, MUC1. This method should also be appropriate for isolating isoforms of many other genes of interest, with one caveat: the primers used are complementary to the start exon (E1) and the end exon (E7) and may miss rare isoforms with alternative start and end sites.
The MUC1 isoforms we describe here are generated by different alternative splicing events including single, double, triple and even quadruple exon skipping, alternative The VNTR region in exon 2 is a characteristic feature of the MUC1 gene. In all the alternatively spliced MUC1 isoforms, this region was spliced out using the same 5 0 splice site and variable 3 0 splice sites ( Fig. 2a-d) . Exon 2 is considerably larger than any typical eukaryotic exons, which normally range from 50 to 250 bp in length [54] . With an average of 80-100 TRs (60 bp per TR), MUC1 exon 2 can be over 6200 bp, longer than many other genes in their entirety. The VNTR sequence contains the core splicing signals such as the 5 0 splice site, 3 0 splice site, and the branch point site. In addition, it contains some cisregulatory elements that have also been described, like the GGxxxxGGG motif which can act as an intron splice enhancer (ISE) [55] . The MUC1 tandem repeat sequence has this motif at the junction of the repeats. N tandem repeats would yield N-1 GGxxxxGGG motifs, the cumulative effect of which will be much stronger than a single enhancer. There are also 3 Nova splicing factor binding sites (YCAY, with Y being any pyrimidine) in each repeat, which when bound by Nova may block exon inclusion [56] . All these characteristics make the VNTR region of exon 2 look and function like an intron, possibly via the formation of tandem repeats with complementary hairpin loops pairing during transcription and the sequences flanking the loops being spliced together by specific spliceosomes [57] [58] [59] .
In contrast to the splicing out of the VNTR region, the cytoplasmic tail region remains mainly intact in almost all the MUC1 short isoforms, preserving important signaling functions [60] or interfering with the function of the fulllength molecule by competing for ligand binding.
Exon 2 is also significantly involved in isoform generation because of the A/G SNP (rs4072037) at position 3506. Though it is a silent SNP that does not change the amino acid encoded, it regulates the 3 0 splice site selection, in most cases, position 3498 being associated with A and 3471 site associated with G [50] . We report here the association of 3250 with G and of position 3259 with A. The A/G SNP can produce different MUC1 short isoform protein products. Both A and G alleles were transcribed and alternatively spliced in the three tumor cell lines, although the frequencies of isoforms generated from different alleles were quite different. Many more cell lines would need to be examined to determine whether the observed difference was significant. There are reports that the A/A allele is associated with a higher risk of gastric cancer [61, 62] .
One surprising observation was that during de novo tumor formation in MUC1KrasPten mice, A to G mutation was observed. As 3506 SNP has been shown to regulate 3 0 splice site selection in intron 1, this change could alter the MUC1 isoform repertoire in cells. We plan to address this in future studies on archival samples of tumor and matching normal tissues, where the outcome of the disease is already known.
The extracellular domain of MUC1, in particular the VNTR region, undergoes profound changes in posttranslational modification during transformation from normal to tumor cells and this may result in changes in the interactions with the extracellular environment and the types of signals transmitted through the MUC1 cytoplasmic tail.
Splicing out of that region, as we saw in all short isoforms, may serve to attenuate the consequences of those changes. It will be important to show convincingly that at least some of the short isoforms have a biological function. Until now, this has been difficult to show for many alternatively spliced genes in cancer [63] . We have begun this by cloning and expressing MUC1/Y-LSP and showing that it can inhibit tumor growth indirectly by stimulating a so far unidentified immune mechanism.
